A Phase 1/2 interventional study of Total Body Irradiation and Alemtuzumab in Sickle Cell Disease and Beta-thalassemia, sponsored by National Heart, Lung, and Blood Institute (NHLBI). Recruiting at 1 site in United States. Open to participants aged 4 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by National Heart, Lung, and Blood Institute (NHLBI) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing alemtuzumab in Anemia, Sickle Cell — 6 open to participants now, 14 under way, none of them phase 3. Alemtuzumab · Anemia, Sickle Cell.
Among the 22 studies testing alemtuzumab in Anemia, Sickle Cell, this one is the 5th largest by planned enrollment, is one of 2 that started in 2026, is one of 5 in phase 1/2, reaches primary completion later than 12 of the 13 other live ones, and was the 21st registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →6 of the 22 studies testing alemtuzumab in Anemia, Sickle Cell are open now, in 2 countries. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Ages up to 22
Paul Szabolcs · Sites in United States
Ages 5–40
Robert Nickel · Sites in United States, Canada
Ages 2–25
University of Calgary · Sites in Canada
Ages 1–19
Paul Szabolcs · Sites in United States
Ages 2 mo–55 yrs
By country, each count listing its studies:
Alemtuzumab: first FDA approval 2001 (LEMTRADA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 4 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 17 · Phase 3 2
First in 1999; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 40 across 770 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 44 across the 22 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 22 has an industry lead sponsor. The 10 most frequent:
National Heart, Lung, and Blood Institute (NHLBI) is the lead sponsor of 1,144 studies on the registry; 71 are open to participants now.
Of its 58 completed or terminated interventional studies of FDA-regulated products, 51 (88%) have results posted.
61 studies in Anemia, Sickle Cell by National Heart, Lung, and Blood Institute (NHLBI): 5 open now, 13 under way, none of them phase 3. Of 47 finished, 9 (19%) have results posted.
Among the 61 studies in Anemia, Sickle Cell by National Heart, Lung, and Blood Institute (NHLBI), this one is the 4th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2026, is one of 8 in phase 1/2, reaches primary completion later than 11 of the 11 other live ones, and was the 61st registered.
National Heart, Lung, and Blood Institute (NHLBI)’s Anemia, Sickle Cell studies by the year they started, since 1977.
3 of the studies testing alemtuzumab in Anemia, Sickle Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04018937Emory UniversityEarly Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation | 2026-11 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT05384756City of Hope Medical CenterTMLI and Alemtuzumab for Treatment of Sickle Cell Disease | 2026-12-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies testing alemtuzumab in Anemia, Sickle Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among National Heart, Lung, and Blood Institute (NHLBI)’s 61 in Anemia, Sickle Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens. The goal is to aim for higher percentage of donor cells to stably remain in the recipients long term.
Study Description:
Our prior non-myeloablative conditioning regimen (03H0170) included 1mg/kg of alemtuzumab divided over 5 days, 300 cGy total body irradiation (TBI), and sirolimus for immune suppression. Sickle disease-free survival (DFS) and overall survival (OS) were 85% and 94% respectively, graft failure 15%, no transplant related mortality (TRM), and acute or chronic GVHD \<5%. A large proportion of patients achieved robust (>=95%) donor myeloid chimerism at day 30, but this proportion decreased quickly to 67.2% at 1, 64.9% at 2, and 60% at 3, and 56.9% at 4 years post-transplant.
A subsequent protocol (000539H) added briquilimab, an antibody targeting CD117 (c-Kit), to alem-300 cGy TBI regimen, but did not reduce the gradual decline in donor myeloid chimerism as originally hypothesized, leading to protocol closure. Rates of graft failure was 20%, no TRM, acute GVHD was 5%, and no chronic GVHD. We now propose to increase TBI to 400 cGy to further deplete host lymphoid and myeloid cells to achieve a higher percentage of donor leukocyte engraftment without substantially increasing toxicity. Since we will continue to use filgrastim to mobilize and collect donor hematopoietic cells, we also add abatacept to preserve the low rates of GVHD.
Objectives:
Primary Objective:
To reduce the proportion of patients with graft failure or donor myeloid chimerism \<95%
Secondary Objectives:
Tertiary Objectives:
Endpoints:
Primary Endpoint: proportion of participants with graft failure or myeloid chimerism \<95% at 1 year post HCT
Secondary Endpoints:
Exploratory Endpoints:
-Quality of life, neuropsychologic function, reproductive health questionnaires, serial testing or imaging of organ function/status
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
RECIPIENT:
Participants must fulfill one disease category (1 or 2) and 3
Patients with sickle cell disease at high risk for disease related morbidity or mortality, defined by having an end-organ damage (A, B, C, D, OR E) or complication(s) not ameliorated by sickle cell-specific therapies (F):
A. Stroke defined as a neurologic event that is accompanied by an infarct on cerebral MRI ORb
B. Abnormal trans-cranial Doppler examination (>=200 cm/s); OR
C. Silent cerebral infarct defined as an infarct-like lesion based on an MRI signal abnormality at least 3 mm in one dimension and visible in two planes on FLAIR or T2- weighted images (or similar image with 3D imaging) and documented neurological examination performed by a neurologist demonstrating the participant has a normal neurologic examination, or an abnormality on examination that could not be explained by the location of the brain lesion(s); OR
D. Sickle cell related renal insufficiency defined by a creatinine level >=1.5 times the and kidney consistent with sickle cell nephropathy OR nephrotic syndrome OR \<60mL/min/1.73m2 for patients \<16 years of age or \<50mL/min for patients >16 years of age OR requiring peritoneal or hemodialysis; OR
Age (Years): \<= 5 / Upper limit of normal serum creatinine (mg/dl): 0.8
Age (Years): 5 \< age \<= 10 / Upper limit of normal serum creatinine (mg/dl): 1.0
Age (Years): 10 \< age \<= 15 / Upper limit of normal serum creatinine (mg/dl): 1.2
Age (Years): > 15 / Upper limit of normal serum creatinine (mg/dl): 1.3
E. Tricuspid regurgitant jet velocity (TRV) of >=2.5 m/s in patients at least 3 weeks after a vaso-occlusive crisis; OR
F. Recurrent severe priapism defined as at least two episodes of an erection lasting >=4 hours requiring medical intervention (e.g. aspiration, injection of vasoconstrictor, prior penile surgery.); OR
G. Sickle hepatopathy defined as EITHER ferritin >1000mcg/L OR direct >0.4 mg/dL at baseline; OR
H. Vaso-occlusive crises: more than 1 hospital admission per year while on a therapeutic dose of sickle cell treatment /medication; OR
I. Acute chest syndrome (ACS): any ACS while on sickle cell treatment /medication
Patients with beta-thalassemia who have grade 2 or 3 iron overload, determined by the presence of 2 or more of the following:
Non disease specific
Agree to use throughout the study and 3 months after abatacept or sirolimus administration.
DONOR:
EXCLUSION CRITERIA
RECIPIENT:
DONOR:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Donors for patients
Other: Research blood draw
Patients with symptomatic sickle cell disease or beta-thalassemia
Radiation: Total Body Irradiation · Drug: Alemtuzumab · Drug: Abatacept · Other: Research blood draw
Total Body Irradiation 400 cGy
1 mg/kg
10 mg/kg x 6
About 5 tablespoons of blood will be collected from donors for research purposes.
Donor myeloid chimerism
percentage of donor myeloid chimerism
Time frame: 1 year
Donor CD3 chimerism
percentage of donor myeloid chimerism
Time frame: 1 year
Overall survival
percentage of patients surviving at 1 year
Time frame: 1 year
Acute Graft versus Host Disease
percentage of patients with Grade 2-4 acute GVHD
Time frame: 1 year
Plan to share: No — We are planning to collect and report data as a group.
Started Jul 2026 (actual). Primary completion is estimated for Jun 2032, 71 months after the start.
Of 37 phase 1/2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 222. This study's planned 71 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Alemtuzumab · Abatacept
National Heart, Lung, and Blood Institute (NHLBI) →